Ingredient · Mineral · Cognitive Companion

Magnesium L-Threonate

Magnesium L-threonate (Magtein™ proprietary form is the most cited preparation). Mineral / sugar-acid chelate.

Cognitive-companion magnesium form — proposed to support brain magnesium status.

Suggested Dose

~1.5–2g Product Dose

Used With

Cognitive Days

Evidence

Tier 2–3 Limited Human

A magnesium form with promising preclinical brain-magnesium delivery — MYKO suggests it as an emerging cognitive-day companion within protocol design, framed as research-promising rather than clinically established.

What It Is

A magnesium form developed for brain delivery research.

Magnesium L-threonate is a magnesium-and-L-threonic-acid compound developed and patented in part to study whether magnesium delivery could be optimized for the central nervous system. Preclinical work using a proprietary preparation reported elevated brain magnesium levels and improvements in synaptic density and learning in rodents — work that has driven its popularity as a "cognitive" magnesium form.

Magnesium L-threonate is not present in any current MYKO capsule formulation. This monograph supports the MYKO website's Education / Stack pages and any future companion-stack product. All copy is framed as protocol education.

Why MYKO Uses It

An emerging cognitive-day pairing within MYKO protocols.

MYKO references magnesium L-threonate as an optional cognitive-day companion to NEUROGENESIS-style days within protocol design. The pairing is mechanistically interesting but should be framed as emerging — the human outcome literature is limited and mostly proprietary-funded.

Found In MYKO Formulas

Where Magnesium L-Threonate appears in the line.

Effects & Experience

Subtle, individual, and not guaranteed.

Customers most often describe a subtle clarity / working-memory effect over weeks of consistent use. Many users feel little to no perceptible change. Effects are not guaranteed.

Within MYKO protocol design, magnesium L-threonate is positioned as a cognitive-day companion — paired with NEUROGENESIS-style work — rather than as an evening or sleep ingredient.

Key Bioactive Compounds

The chemistry MYKO selects for.

Elemental magnesium

Same essential-mineral cofactor activity described in the Magnesium Glycinate monograph.
L-threonic acid

A sugar-acid metabolite of vitamin C. Proposed to support magnesium transport across the blood-brain barrier in preclinical research.

Mechanisms in the Body

Three pathways, three evidence levels.

Mechanism strength is presented separately so you can see what is human-supported, what is preclinical, and what is traditional theory.

Human-Supported

A small human RCT (Liu et al., 2016) reported improvements in cognitive performance scores in older adults supplemented with magnesium L-threonate — a single, sponsor-adjacent study.

Preclinical / Mechanistic

Preclinical work with the proprietary magnesium-threonate preparation reported elevated cerebrospinal-fluid magnesium and improvements in long-term potentiation and learning measures in rodent models (Slutsky et al., 2010; subsequent rodent work).
Magnesium acts as a natural NMDA receptor antagonist; brain-level magnesium status is mechanistically linked to synaptic function.

Traditional / Theoretical

Magnesium L-threonate is a modern formulation; there is no traditional-use lineage specific to this form.

Evidence Grade

How MYKO grades this ingredient.

Overall Grade

Tier 2–3 — limited but promising human evidence; supportive preclinical evidence; significant proprietary-funding context.

Strongest Areas

Preclinical brain-magnesium delivery (Tier 2–3); essential-mineral nutritional role of magnesium itself (Tier 1).

Weaker / Emerging

Standalone cognitive claims in healthy adults; specific memory-improvement percentages; broad anti-aging claims.

Claim Caution

Moderate

Reason

Magnesium L-threonate is mechanistically interesting and the preclinical work is meaningful, but the human-outcome literature is small and largely sponsor-adjacent. Customer copy should respect that.

Science Hub

For the customer who wants the full picture.

Read the Deeper Technical Version

Magnesium L-threonate combines elemental magnesium with L-threonic acid — a sugar-acid metabolite of vitamin C. The preclinical case for the form is led by Slutsky et al. (2010) and subsequent rodent work using the proprietary Magtein™ preparation, which reported elevated cerebrospinal-fluid magnesium and improvements in long-term potentiation and learning. The headline human work (Liu et al., 2016) is a small RCT in older adults with sponsor-adjacent funding context.

Mechanistically, magnesium acts as a natural NMDA receptor antagonist, and brain-level magnesium status is linked to synaptic function in preclinical models. Whether the form delivers a meaningful and unique cognitive benefit in healthy adults beyond what other magnesium forms provide remains an open question.

Within MYKO protocol design, magnesium L-threonate is positioned as a cognitive-day companion — paired with NEUROGENESIS-style days. It is not in any current MYKO capsule formulation. Customer copy must respect the limited human-evidence base and avoid overstating outcomes.

References cited on this page (1)

Citations referenced inline in the mechanisms and technical sections above. For the full evidence base across all MYKO ingredients, see the Library. Sources are listed by author and year only — full citation details available on request.

Liu et al., 2016

Safety Notes

What to know before using.

Generally well tolerated. GI tolerance is comparable to or better than other magnesium forms.
Use caution with kidney disease — kidneys regulate magnesium clearance.
May interact with antibiotics, bisphosphonates, and some blood-pressure medications. Space dosing.
Use caution in pregnancy and breastfeeding — limited human data on this specific form.
Most adults tolerate the typical 1.5–2g/day product dose (≈ 144mg elemental magnesium).

Research Notes

What's supported, what's emerging.

What is reasonably supported: preclinical brain-magnesium delivery; essential-mineral role of magnesium.

What is still emerging: human cognitive outcomes; long-term safety; comparative efficacy versus glycinate or citrate.

What should not be claimed strongly: "reverses cognitive aging," "prevents Alzheimer's," "treats memory loss," "clinically proven" without acknowledging the limited human evidence base.

Where more human research is needed: independent (non-sponsor) RCTs; long-term safety data; head-to-head comparisons with other forms for cognitive outcomes specifically.

Explore Ingredients

All Twelve in MYKO's Library.

Lion's Mane Cordyceps Shilajit Reishi Chaga Turkey Tail Active Botanical P. Ochra 5 Mushroom Complex Niacin · B3 Mag · Glycinate Mag · L-Threonate

These statements have not been evaluated by the U.S. Food and Drug Administration. MYKO products are not intended to diagnose, treat, cure, or prevent any disease.

Information on this site is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment. Consult a qualified healthcare practitioner before beginning any new supplement, particularly if you are pregnant, breastfeeding, taking medication, or managing a medical condition.